Fate Therapeutics Inc (FATE) Live Share Price, Invest From India

Fate Therapeutics Inc Stock Performance

as on May 22, 2026 at 2:16 pm IST

Day's Low
Day's High
$1.78
Day's Price Range
$2.15
$2.10
15.24%
Downside
2.38%
Upside
52 Week's Low
52 Week's High
$0.91
52-Week Price Range
$2.47
$2.10
56.67%
Downside
17.38%
Upside

Fate Therapeutics Inc share price movements today

Previous Close: $1.84
Open: $1.83
Volume: 7.8M
Day's Low - High: $1.78 - $2.15
52 Week Low - High: $0.91 - $2.47

Fate Therapeutics Inc Historical Returns

1 Month Return: + 53.28 %
3 Month Return: + 43.84 %
1 Year Return: + 75 %
3 Year Return: -59.85 %
5 Year Return: -97.15 %

Fate Therapeutics Inc Stock Fundamentals & Key Indicators

Check Fate Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$244.8M

EPS (TTM)

-0.9986

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-125.8M

Revenue (TTM)

6.3M

Profit Margin

0.00%

Return On Equity TTM

-55.50%

Fate Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Fate Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Fate Therapeutics Inc	HOLD	$244.8M	-97.15%	NA	0.00%
Alnylam Pharmaceuticals Inc	BUY	$39.9B	114.56%	75.18	12.55%
Vertex Pharmaceuticals Inc	BUY	$109.2B	103.13%	25.58	35.51%
Regeneron Pharmaceuticals Inc	BUY	$68.1B	26.81%	15.87	29.65%

Stock Returns calculator for Fate Therapeutics Inc Stock including INR - Dollar returns

The Fate Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Fate Therapeutics Inc investment value today

Current value as on today

₹1,96,650

Returns

₹96,650

(+96.65%)

Returns from Fate Therapeutics Inc Stock

₹75,000 (+75%)

Dollar Impact

₹21,650 (+21.65%)

Analyst Recommendation on Fate Therapeutics Inc Stock

Based on 26 analysts

HOLD

42.31%

Buy

53.85%

Hold

3.85%

Sell

Based on 26 analysts, 53.85% of analysts recommend a 'HOLD' rating for Fate Therapeutics Inc. Average target price of $5.39

Fate Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Fate Therapeutics Inc.

What analysts predicted

61.04%UPSIDE

Target Price

$5.39

Current Price

$2.1

Analyzed by

26 Analysts

Target

$5.39

Fate Therapeutics Inc target price $5.39, a slight upside of 61.04% compared to current price of $2.1. According to 26 analysts rating.

Indian Investors' Interest in Fate Therapeutics Inc Stock

Search interest for Fate Therapeutics Inc Stock has increased by 93% in the last 30 days, reflecting an upward trend in search activity.

Time period: April 22, 2026 to May 22, 2026

Change:93% versus previous 30 day period

Fate Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	1	1	6	3	1	1	1	1	1	1
Gross Profit	-3	-2	2	3	1	1	1	1	1	-1
Operating Income	-48	-51	-45	-52	-61	-41	-36	-34	-34	-33
EBITDA	-43	-46	-40	-47	-42	-37	-30	-29	-31	-30
Interest Expense	9	-	-	-	-	-	-	-	-	-
Depreciation	4	4	4	4	4	3	3	3	3	2
Income Before Tax	-44	-48	-38	-47	-52	-37	-34	-32	-32	-31
Income Tax Expense	18	4	-	-	-4	-	-	-	-	-
Net Income	-44	-48	-38	-47	-52	-37	-34	-32	-32	-31
Net Profit Margin	-2632.58%	-2493.71%	-567.44%	-1551.01%	-2803.92%	-2309.45%	-1786.58%	-1852.38%	-2364.79%	-2402.85%

Fate Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	4	4	4	10	31	55	96	63	13	6
Gross Profit	-22	-30	-51	10	-94	49	96	-93	13	-6
Operating Income	-31	-42	-67	-100	-128	-216	-308	-190	-210	-147
EBITDA	-30	-40	-63	-94	-124	-211	-294	-172	-176	-127
Interest Expense	1	1	1	1	2	4	5	-	-	-
Depreciation	-	0	1	2	3	5	13	18	18	12
Income Before Tax	-33	-42	-66	-98	-173	-212	-281	-160	-186	-136
Income Tax Expense	0	0	2	0	-3	-5	-26	18	-	-
Net Income	-33	-42	-66	-98	-173	-212	-255	-160	-186	-136
Net Profit Margin	-760.15%	-1046.08%	-1405.02%	-919.00%	-551.59%	-379.89%	-264.86%	-253.30%	-1366.46%	-2051.08%

Fate Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-48	-38	-47	-52	-37	-34	-32	-32	-31
Operating Cash Flow	-33	-32	-29	-27	-33	-24	-24	-23	-30
Investing Cash Flow	17	-53	25	22	42	19	21	27	23
Financing Cash Flow	95	1	-	3	-	1	2	1	-
Change in Cash	79	-84	0	-1	8	-3	0	6	-7

Fate Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-42	-66	-98	-173	-212	-281	-160	-186	-136
Operating Cash Flow	-36	-38	-83	-39	-162	-248	-132	-122	-106
Investing Cash Flow	-10	0	-157	-161	-324	166	112	12	111
Financing Cash Flow	47	140	149	282	453	9	0	99	5
Change in Cash	0	101	-90	67	-33	-72	-19	-5	10

Global Institutional Holdings in Fate Therapeutics Inc

Funds	Holdings
Acadian Asset Management LLC	2.33%
UBS Group AG	0.83%
BlackRock Inc	8.75%
TANG CAPITAL MANAGEMENT LLC	1%
Monaco Asset Management	0.71%

See all

Insights on Fate Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 1 Year
In the last 1 year, FATE has outperformed top 5 stocks with highest market-cap in its industry
POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -32.37M → -31.21M (in $), with an average increase of 3.7% per quarter
POSITIVE IMPACT
Price Rise
In the last 7 days, FATE stock has moved up by 19.7%
NO EFFECT
Against Peers
In the last 3 years, Fate Therapeutics, Inc. Common Stock has experienced a drawdown of -59.8%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 45.3%
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 4 quarters, 1.90M → 1.29M (in $), with an average decrease of 11.7% per quarter

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.

Organisation	Fate Therapeutics Inc
Headquarters	12278 Scripps Summit Drive, San Diego, CA, United States, 92131
Industry	Biotechnology
CEO	Dr. Bahram Valamehr M.B.A., Ph.D.
E-voting on shares	Click here to vote

Key Management of Fate Therapeutics Inc

Name	Title
Mr. Kamal Adawi M.S., MBA	CFO & Treasurer
Ms. Cindy R. Tahl J.D.	Chief Legal & Compliance Officer and Corporate Secretary
Dr. Martin Hosking	Head of Research
Dr. Tunde Babalola Ph.D.	Senior Vice President of Technical Operations & Quality
Mr. Andrew Henry	Senior Vice President of Clinical Operations
Dr. Bahram Valamehr M.B.A., Ph.D.	President, CEO & Director
Ms. Jessica Francis	Senior Vice President of Human Resources & Operations
Mr. Ryan Douglas	Senior Director of Investor Relations & Business Development
Dr. Yu Cai J.D., Ph.D.	Head of Intellectual Property & Assistant General Counsel
Ms. Kate Duvall	Corporate Controller

FAQs

What is Fate Therapeutics Inc share price today?

Fate Therapeutics Inc share price today is $2.1 as on May 22, 2026 at 8:46 am IST at the close of the market. Fate Therapeutics Inc share today touched a day high of $2.15 and a low of $1.78.

What is the 52 week high and 52 week low for Fate Therapeutics Inc share?

Fate Therapeutics Inc share touched a 52 week high of $2.47 on May 8, 2026 and a 52 week low of $0.91 on August 11, 2025. Fate Therapeutics Inc stock price today i.e. May 22, 2026 at 8:46 am IST is closed at $2.1,which is 14.81% down from its 52 week high and 130.77% up from its 52 week low.

What is Fate Therapeutics Inc's market capitalisation today?

Fate Therapeutics Inc market capitalisation is $0.00T as on May 22, 2026 at 8:46 am IST.

How to invest in Fate Therapeutics Inc Stock (FATE) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Fate Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Fate Therapeutics Inc Shares that will get you 0.7143 shares as per Fate Therapeutics Inc share price of $2.1 per share as on May 22, 2026 at 8:46 am IST.

What is the minimum amount required to buy Fate Therapeutics Inc Stock (FATE) from India?

Indian investors can start investing in Fate Therapeutics Inc (FATE) shares with as little as ₹96.19 or $1 (as of May 22, 2026 at 5:40 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹961.90 in Fate Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on May 22, 2026 at 5:40 pm IST). Based on Fate Therapeutics Inc share’s latest price of $2.1 as on May 22, 2026 at 8:46 am IST, you will get 4.7619 shares of Fate Therapeutics Inc. Learn more about fractional shares .

What are the returns that Fate Therapeutics Inc has given to Indian investors in the last 5 years?

Fate Therapeutics Inc stock has given -97.15% share price returns and 32.3% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?